Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca CEO Brennan Talks About Cutting Deals and Dealing With Change

Executive Summary

PhRMA's new chairman, AstraZeneca CEO David Brennan, wants to make a deal on health reform - but not necessarily the kind of tradeoff the industry made on the Medicare drug benefit

You may also be interested in...



PDUFA V "Wish List" From Consumers Union Includes Comparative Effectiveness Standard

Formally at the user fee negotiation table for the first time, the advocacy group wants new drugs to be tested against the "best practice" for treating a disease.

Merck Buys Schering-Plough -- and Time

Merck's acquisition of Schering-Plough is all about buying breathing room, relief from what looks to be a 4-year, 50% earnings decline as key products go generic. Moreover, the relief comes relatively inexpensively (unless J&J steps in with a counteroffer), a fact that reflects Schering's lack of strategic options. In this interview, Merck's R&D boss Peter Kim and chief strategist, Mervyn Turner, explain the key pipeline and marketing complementarities and cost-cutting possibilities which prompted the deal -- and how they plan to integrate the two businesses.

AstraZeneca R&D: Aim Early To Cut Cycle Time, Build Phase II Pipeline

Current R&D strategy emphasizes improvements to R&D processes, like trying to reduce costs and cycle time. Making go/no-go decisions earlier on is also a goal, R&D execs say in an interview. The firm is in a building phase as it makes up for some major Phase III failures in recent years. AstraZeneca's current late-stage pipeline is mostly focused on lifecycle management

Related Content

Topics

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel